Galapagos is committed to establishing itself as valued scientific partner in the race to combat idiopathic pulmonary fibrosis (IPF). We have growing pipeline of new molecules with distinct mode of action which are moving rapidly in clinical development. Our most advanced molecule GLPG1690 is an oral, once daily autotaxin inhibitor currently in Phase 3 studies: the largest clinical program ever undertaken in IPF.
GLPG1690
In April 2018, we announced the design of this worldwide Phase 3 program to evaluate GLPG1690 in IPF patients, and the first patient was dosed in December 2018. The ISABELA Phase 3 program is intended to support both New Drug Application (NDA) and Market Authorization Application (MAA) submissions for GLPG1690 in respectively the US and EU. Read more at www.isabelastudies.com.
In the FLORA Phase 2a study in IPF patients, Galapagos reported a halt in disease progression, target engagement, and favorable safety and tolerability. GLPG1690 is fully proprietary to Galapagos and has been granted orphan status in Europe and the US.
In January 2019, Galapagos initiated the Phase 2 NOVESA trial with GLPG1690 in systemic schlerosis patients.
GLPG1205
In July 2018, we announced the design for the PINTA Phase 2 trial with GLPG1205 in IPF, and the first patient was dosed in October 2018. GLPG1205 is a GPR84 inhibitor discovered by and fully proprietary to Galapagos. GLPG1205 showed a reduction in signs and symptoms in IPF animal models and has shown favorable tolerability in healthy volunteers and in ulcerative colitis patients in previous trials.
Related publications